{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-352186","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2026-08-14T20:05:16+00:00","discovered_at":"2026-08-14T20:10:00.268143+00:00","generated_at":"2026-08-14T20:10:18.530447+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"NewAmsterdam Pharma appoints Robert Gunning as principal accounting officer","bullets":["Robert W. Gunning, 55, appointed principal accounting officer effective Aug 10, 2026, succeeding Louise Kooij (departs Aug 31, 2026).","Gunning joined as VP Controller; base salary $375,000/year, target bonus 30% of base, prorated for first year.","Equity grant: RSU covering 3,200 ordinary shares and option for 14,000 shares under 2024 Inducement Plan.","Prior roles: Interim Controller at Altimmune (Apr-Jul 2026), VP Finance/Controller at Y-mAbs (2022-2026), VP Controller at Excision Biotherapeutics (2021-2022)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-352186","json":"https://secwatch.observer/filing/0001193125-26-352186.json","markdown":"https://secwatch.observer/filing/0001193125-26-352186.md","text":"https://secwatch.observer/filing/0001193125-26-352186.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526352186/0001193125-26-352186-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526352186/nams-20260810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T20:10:18.530447+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}